Vitamin D receptors (VDR), hydroxylases CYP27B1 and CYP24A1 and retinoid-related orphan receptors (ROR) level in human uveal tract and ocular melanoma with different melanization levels.
25-Hydroxyvitamin D3 1-alpha-Hydroxylase
/ metabolism
Adult
Aged
Aged, 80 and over
Female
Gene Expression Regulation, Neoplastic
Humans
Male
Melanins
/ metabolism
Melanoma
/ metabolism
Middle Aged
Nuclear Receptor Subfamily 1, Group F, Member 1
/ metabolism
Nuclear Receptor Subfamily 1, Group F, Member 3
/ metabolism
Receptors, Calcitriol
/ metabolism
Uvea
/ metabolism
Uveal Neoplasms
/ metabolism
Vitamin D3 24-Hydroxylase
/ metabolism
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
24 06 2019
24 06 2019
Historique:
received:
02
11
2018
accepted:
23
05
2019
entrez:
26
6
2019
pubmed:
27
6
2019
medline:
24
10
2020
Statut:
epublish
Résumé
In recent years, a significant number of studies have investigated the preventive role of vitamin D in a number of different neoplasms. In this study, we analyze various components of the vitamin D signaling pathways in the human uveal tract and uveal melanoma, including analysis of the expression of vitamin D receptors (VDR), the activating and inactivating hydroxylases, respectively, CYP27B1 and CYP24A1, and the retinoic acid-related orphan receptors (ROR) α (RORα) and γ (RORγ) in these tissues. We further analyzed the expression of VDR, CYP27B1, CYP24A1, and ROR in relation to melanin levels, clinical stage and prognosis. Our study indicated that the uveal melanoma melanin level inversely correlated with VDR expression. We further showed that vitamin D is metabolized in uveal melanoma. This is significant because until now there has been no paper published, that would describe presence of VDR, hydroxylases CYP27B1 and CYP24A1, and RORα and RORγ in the human uveal tract and uveal melanomas. The outcomes of our research can contribute to the development of new diagnostic and therapeutic methods in uveal tract disorders, especially in uveal melanoma. The presented associations between vitamin D signaling elements and uveal melanoma in comparison to uveal tract encourage future clinical research with larger patients' population.
Identifiants
pubmed: 31235702
doi: 10.1038/s41598-019-45161-8
pii: 10.1038/s41598-019-45161-8
pmc: PMC6591242
doi:
Substances chimiques
Melanins
0
Nuclear Receptor Subfamily 1, Group F, Member 1
0
Nuclear Receptor Subfamily 1, Group F, Member 3
0
RORA protein, human
0
RORC protein, human
0
Receptors, Calcitriol
0
Vitamin D3 24-Hydroxylase
EC 1.14.15.16
25-Hydroxyvitamin D3 1-alpha-Hydroxylase
EC 1.14.15.18
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
9142Subventions
Organisme : BLRD VA
ID : I01 BX004293
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR071189
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR073004
Pays : United States
Organisme : Intramural NIH HHS
ID : Z01 ES101586
Pays : United States
Références
Pigment Cell Melanoma Res. 2012 Jan;25(1):14-27
pubmed: 21834848
PLoS One. 2016 Apr 01;11(4):e0152889
pubmed: 27035345
Mayo Clin Proc. 2014 Apr;89(4):429-33
pubmed: 24684870
J Photochem Photobiol B. 1999 Jun;50(2-3):197-203
pubmed: 10577051
Exp Dermatol. 2015 Apr;24(4):258-9
pubmed: 25496715
Anticancer Res. 1998 Sep-Oct;18(5B):3709-15
pubmed: 9854482
Physiol Rev. 2016 Jan;96(1):365-408
pubmed: 26681795
Exp Eye Res. 2015 May;134:101-10
pubmed: 25724179
Hum Pathol. 2013 Oct;44(10):2071-4
pubmed: 23791398
Adv Dev Biol. 2006;16:313-355
pubmed: 18418469
J Histochem Cytochem. 2004 Jul;52(7):985-9
pubmed: 15208365
Mil Med. 2014 Jan;179(1):81-4
pubmed: 24402990
Physiol Rev. 2004 Oct;84(4):1155-228
pubmed: 15383650
Nat Rev Cancer. 2014 May;14(5):342-57
pubmed: 24705652
Arch Biochem Biophys. 2014 Dec 1;563:79-93
pubmed: 24997364
Ophthalmology. 2016 Apr;123(4):898-907
pubmed: 26854035
Int J Mol Sci. 2018 Apr 01;19(4):
pubmed: 29614755
Sci Rep. 2017 Sep 12;7(1):11434
pubmed: 28900196
J Steroid Biochem Mol Biol. 2018 Mar;177:159-170
pubmed: 28676457
Ophthalmology. 2007 Dec;114(12):2309-15
pubmed: 17498805
Invest Ophthalmol Vis Sci. 2014 Apr 07;55(4):2140-7
pubmed: 24576880
Nutrients. 2013 Jul 05;5(7):2502-21
pubmed: 23857223
Sci Rep. 2015 Oct 08;5:14875
pubmed: 26445902
Structure. 2002 Dec;10(12):1697-707
pubmed: 12467577
Cell Death Differ. 2002 Nov;9(11):1167-71
pubmed: 12404115
FASEB J. 2012 Sep;26(9):3901-15
pubmed: 22683847
Arch Ophthalmol. 2005 Dec;123(12):1639-43
pubmed: 16344433
Cell Physiol Biochem. 2015;36(1):299-305
pubmed: 25967968
Clin Oncol (R Coll Radiol). 2016 Aug;28(8):e17-27
pubmed: 26915706
Int J Mol Sci. 2014 Oct 20;15(10):19000-17
pubmed: 25334067
Eye (Lond). 2015 Aug;29(8):1027-35
pubmed: 26248525
PLoS One. 2016 Feb 19;11(2):e0149294
pubmed: 26894581
Br J Cancer. 2014 May 27;110(11):2772-84
pubmed: 24714744
Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10132-7
pubmed: 10963675
Arch Ophthalmol. 2009 Aug;127(8):989-98
pubmed: 19667335
Am J Clin Nutr. 2004 Dec;80(6 Suppl):1678S-88S
pubmed: 15585788
Curr Opin Toxicol. 2018 Apr;8:66-80
pubmed: 29568812
Int J Cancer. 2009 Mar 15;124(6):1470-7
pubmed: 19085934
Science. 2000 Jun 30;288(5475):2369-73
pubmed: 10875923
Oncotarget. 2016 Sep 27;7(39):63261-63282
pubmed: 27542227
Lab Invest. 2017 Jun;97(6):706-724
pubmed: 28218743
J Steroid Biochem Mol Biol. 2017 Oct;173:42-56
pubmed: 27693422
PLoS Genet. 2008 Feb 29;4(2):e1000023
pubmed: 18454201
Endocr Relat Cancer. 2012 May 03;19(3):R51-71
pubmed: 22383428
J Lipid Res. 2014 Jan;55(1):13-31
pubmed: 23564710
Oncol Rep. 2015 Feb;33(2):599-606
pubmed: 25501638
FASEB J. 2014 Jul;28(7):2775-89
pubmed: 24668754
Trends Endocrinol Metab. 2012 Dec;23(12):619-27
pubmed: 22789990
Dermatoendocrinol. 2013 Jan 1;5(1):51-108
pubmed: 24494042
Eye (Lond). 2017 Feb;31(2):241-257
pubmed: 27911450
Br J Cancer. 2011 Dec 6;105(12):1874-84
pubmed: 22095230
Nutrients. 2017 Oct 13;9(10):
pubmed: 29027953
Hum Pathol. 2013 Mar;44(3):374-87
pubmed: 22995334
Int J Mol Sci. 2018 Mar 17;19(3):
pubmed: 29562608
Cancer Lett. 2015 Nov 1;368(1):1-6
pubmed: 26276715
Mayo Clin Proc. 2013 Jul;88(7):720-55
pubmed: 23790560
Br J Ophthalmol. 2009 Sep;93(9):1129-31
pubmed: 19704035
Cancer. 1998 Oct 15;83(8):1664-78
pubmed: 9781962
Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4651-9
pubmed: 14578381
Nucleic Acids Res. 2012 Sep 1;40(17):8519-35
pubmed: 22753030
Exp Dermatol. 2011 Jan;20(1):7-13
pubmed: 21197695
Biochem J. 2012 Jan 1;441(1):61-76
pubmed: 22168439
Hum Pathol. 2011 May;42(5):618-31
pubmed: 21292298
J Endocrinol Invest. 2018 Oct;41(10):1199-1210
pubmed: 29464660
Nature. 1979 Mar 8;278(5700):180-2
pubmed: 763363
Int J Mol Sci. 2015 Oct 15;16(10):24369-86
pubmed: 26501255
Arch Biochem Biophys. 2012 Jul 1;523(1):30-6
pubmed: 22310641
Mol Cell Endocrinol. 2014 Mar 5;383(1-2):181-92
pubmed: 24382416
J Biol Chem. 2004 Apr 2;279(14):14033-8
pubmed: 14722075
Anticancer Res. 2014 Jun;34(6):2735-43
pubmed: 24922634
Chem Biol. 2014 Mar 20;21(3):319-29
pubmed: 24529992
Med Sci Monit. 2017 May 10;23:2211-2216
pubmed: 28487505
Ophthalmology. 2011 Sep;118(9):1881-5
pubmed: 21704381
Nucl Recept Signal. 2009;7:e003
pubmed: 19381306
Ocul Oncol Pathol. 2017 Sep;3(3):193-198
pubmed: 29071269